{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T18:33:37Z","timestamp":1793385217768,"version":"4.5.0"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Crohn\u2019s and Colitis Foundation","award":["695759"],"award-info":[{"award-number":["695759"]}],"id":[{"id":"https:\/\/ror.org\/05f2xbq60","id-type":"ROR","asserted-by":"crossref"}]},{"name":"EnLiSense LLC"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Wearable sensors present an opportunity to monitor inflammation via noninvasive media such as perspiration, which may be sampled continuously to track biomarkers in inflammatory bowel disease (IBD). Here we demonstrate the use of a perspiration sensor for C-reactive protein (CRP) and calprotectin and their clinical significance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Thirty-three patients with IBD were enrolled in a cross-sectional study of CRP and calprotectin perspiration expression compared to expression in serum and stool, respectively. Perspiration on-body measurements were obtained every minute using a wearable sensor worn for 40-130\u2009minutes during standard of care assessment. Synchronously collected serum levels were measured, as was fecal calprotectin from a subcohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Principal component analysis of demographic data identified age, disease activity, and diagnosis as the major contributors to variance in the dataset. When endoscopic scores were incorporated into the PCA, both disease activity and endoscopy score were identified as contributing most strongly to the primary variance. In perspiration and serum, median CRP was observed to be elevated in patients with Crohn\u2019s disease (CD) compared to ulcerative colitis, while median calprotectin was elevated in UC compared to CD. Median calprotectin across perspiration, serum, and stool was observed to be elevated in IBD of the colon over isolated ileal IBD. Furthermore, median perspiration and serum CRP were elevated in patients under 40\u2009years of age compared to those 40 and older, whereas median perspiration, serum, and fecal calprotectin were elevated in patients 40 and older compared to the younger cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We report the use of a noninvasive perspiration sensor for tracking inflammatory markers in patients with IBD and demonstrate consistency of perspiration CRP and calprotectin measurements with corresponding serum and stool measurements.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ibd\/izag173","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T11:52:08Z","timestamp":1786017128000},"page":"2095-2102","source":"Crossref","is-referenced-by-count":1,"title":["Wearable perspiration sensor for continuous inflammation tracking in inflammatory bowel disease"],"prefix":"10.1093","volume":"32","author":[{"given":"Sarah","family":"Shahub","sequence":"first","affiliation":[{"name":"University of Texas at Dallas Bioengineering Department, , Richardson, TX,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai-Chun","family":"Lin","sequence":"additional","affiliation":[{"name":"University of Texas at Dallas Bioengineering Department, , Richardson, TX,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie K","family":"Choi","sequence":"additional","affiliation":[{"name":"University of Chicago Medicine Inflammatory Bowel Disease Center, , Chicago, IL,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole M","family":"Garcia","sequence":"additional","affiliation":[{"name":"University of Chicago Medicine Inflammatory Bowel Disease Center, , Chicago, IL,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sriram","family":"Muthukumar","sequence":"additional","affiliation":[{"name":"Enlisense LLC , Allen, TX 75013,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5647-1723","authenticated-orcid":false,"given":"David T","family":"Rubin","sequence":"additional","affiliation":[{"name":"University of Chicago Medicine Inflammatory Bowel Disease Center, , Chicago, IL,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2404-3801","authenticated-orcid":false,"given":"Shalini","family":"Prasad","sequence":"additional","affiliation":[{"name":"University of Texas at Dallas Bioengineering Department, , Richardson, TX,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,28]]},"reference":[{"key":"2026103014075976400_izag173-B1","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1111\/j.1365-2362.1982.tb02244.x","article-title":"Serum levels of C-reactive protein in Crohn\u2019s disease and ulcerative colitis","volume":"12","author":"Fagan","year":"1982","journal-title":"Eur J Clin Invest"},{"key":"2026103014075976400_izag173-B2","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1097\/mib.0000000000000057","article-title":"Meta-analysis","volume":"20","author":"Lin","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"2026103014075976400_izag173-B3","doi-asserted-by":"publisher","first-page":"otab059","DOI":"10.1093\/crocol\/otab059","article-title":"Silent Inflammatory Bowel Disease","volume":"3","author":"Coates","year":"2021","journal-title":"Crohns Colitis 360"},{"key":"2026103014075976400_izag173-B4","doi-asserted-by":"publisher","first-page":"e10220","DOI":"10.1002\/btm2.10220","article-title":"Temporal profiling of cytokines in passively expressed sweat for detection of infection using wearable device","volume":"6","author":"Jagannath","year":"2021","journal-title":"Bioeng Transl Med"},{"key":"2026103014075976400_izag173-B5","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.1093\/ibd\/izae054","article-title":"Continuous Monitoring of CRP, IL-6, and calprotectin in inflammatory bowel disease using a perspiration-based wearable device","volume":"30","author":"Shahub","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"2026103014075976400_izag173-B6","doi-asserted-by":"publisher","first-page":"555","DOI":"10.3899\/jrheum.180537","article-title":"Serum biomarkers for prediction of response to methotrexate monotherapy in early rheumatoid arthritis: results from the SWEFOT trial","volume":"46","author":"Hambardzumyan","year":"2019","journal-title":"J Rheumatol"},{"key":"2026103014075976400_izag173-B7","doi-asserted-by":"publisher","first-page":"114765","DOI":"10.1016\/j.eswa.2021.114765","article-title":"Feature selection for classification using principal component analysis and information gain","volume":"174","author":"Omuya","year":"2021","journal-title":"Expert Syst Appl"},{"key":"2026103014075976400_izag173-B8","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/00365529950172844","article-title":"Morphologic criteria applicable to biopsy specimens for effective distinction of inflammatory bowel disease from other forms of colitis and of Crohn's disease from ulcerative colitis","volume":"34","author":"Tanaka","year":"1999","journal-title":"Scand J Gastroenterol"},{"key":"2026103014075976400_izag173-B9","doi-asserted-by":"crossref","first-page":"otab028","DOI":"10.1093\/crocol\/otab028","article-title":"Patient Adherence to Fecal Calprotectin Testing Is Low Compared to Other Commonly Ordered Tests in Patients With Inflammatory Bowel Disease","volume":"3","author":"Khakoo","year":"2021","journal-title":"Crohns Colitis 360"},{"key":"2026103014075976400_izag173-B10","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.cgh.2017.10.019","article-title":"Patient-reported outcome measures for use in clinical trials and clinical practice in inflammatory bowel diseases: a systematic review","volume":"16","author":"de Jong","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026103014075976400_izag173-B11","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s41687-018-0049-2","article-title":"Development and validation of the Ulcerative Colitis patient-reported outcomes signs and symptoms (UC-pro\/SS) diary","volume":"2","author":"Higgins","year":"2017","journal-title":"J Patient Rep Outcomes"},{"key":"2026103014075976400_izag173-B12","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s41687-018-0044-7","article-title":"Development and validation of the Crohn's disease patient-reported outcomes signs and symptoms (CD-PRO\/SS) diary","volume":"2","author":"Higgins","year":"2017","journal-title":"J Patient Rep Outcomes"},{"key":"2026103014075976400_izag173-B13","doi-asserted-by":"publisher","first-page":"20150202","DOI":"10.1098\/rsta.2015.0202","article-title":"Principal component analysis: a review and recent developments","volume":"374","author":"Jolliffe","year":"2016","journal-title":"Philos Trans A Math Phys Eng Sci"},{"key":"2026103014075976400_izag173-B14","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1136\/gut.2007.146357","article-title":"C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. results from a prospective population-based study","volume":"57","author":"Henriksen","year":"2008","journal-title":"Gut"},{"key":"2026103014075976400_izag173-B15","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1002\/jgh3.12068","article-title":"Fecal calprotectin correlates with active colonic inflammatory bowel disease but not with small intestinal Crohn\u2019s disease activity","volume":"2","author":"Zittan","year":"2018","journal-title":"JGH Open"},{"key":"2026103014075976400_izag173-B16","year":"2025"},{"key":"2026103014075976400_izag173-B17","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/j.cgh.2025.07.009","article-title":"Efficacy of advanced therapies in achieving remission by disease location in Crohn\u2019s disease: a systematic review and meta-analysis","volume":"24","author":"Lee","year":"2026","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026103014075976400_izag173-B18","doi-asserted-by":"publisher","first-page":"841","DOI":"10.3109\/00365521.2015.1008035","article-title":"Impact of disease location on fecal calprotectin levels in Crohn\u2019s disease","volume":"50","author":"Gecse","year":"2015","journal-title":"Scand J Gastroenterol"},{"key":"2026103014075976400_izag173-B19","doi-asserted-by":"publisher","first-page":"595","DOI":"10.5009\/gnl15411","article-title":"Disease phenotype, activity and clinical course prediction based on C-reactive protein levels at diagnosis in patients with Crohn\u2019s disease: results from the CONNECT study","volume":"10","author":"Kwon","year":"2016","journal-title":"Gut Liver"},{"key":"2026103014075976400_izag173-B20","doi-asserted-by":"publisher","first-page":"227","DOI":"10.3390\/jpm14030227","article-title":"Diagnostic accuracy of fecal calprotectin in discriminating organic-inflammatory gastrointestinal diseases and functional gastrointestinal disorders in older patients","volume":"14","author":"Gallo","year":"2024","journal-title":"J Pers Med"}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/32\/11\/2095\/70832512\/izag173.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/32\/11\/2095\/70832512\/izag173.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T18:08:08Z","timestamp":1793383688000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/32\/11\/2095\/8772797"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,28]]},"references-count":20,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,8,28]]},"published-print":{"date-parts":[[2026,11,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izag173","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,11]]},"published":{"date-parts":[[2026,8,28]]}}}